Progress in mining the human proteome for disease applications

OMICS A Journal of Integrative Biology

Volumn 15, Issue 3, 2011, Pages 133-139

  Hanash, Sam ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

ARTICLE; GENERAL ASPECTS OF DISEASE; GENOMICS; HUMAN; PLASMA; PRIORITY JOURNAL; PROTEOMICS; SERUM;

BLOOD PROTEINS; COMPUTATIONAL BIOLOGY; DISEASE; HUMANS; PROTEOME; PROTEOMICS;

EID: 79952496444     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2010.0111     Document Type: Article

References (53)

1. (2010). A gene-centric human proteome project: HUPO-the Human Proteome organization. Mol Cell Proteomics 9, 427-429.
2. Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712. (Pubitemid 38489892)
3. Apweiler, R., Aslanidis, C., Deufel, T., Gerstner, A., Hansen, J., Hochstrasser, J., et al. (2009). Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 47, 724-744.
4. Beretta, L. (2009). Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery. Cancer Lett 286, 134-139.
5. Berglund, L., Bjorling, E., Oksvold, P., Fagerberg, L., Asplund, A., Szigyarto, C. A., et al. (2008). A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7, 2019-2027.
6. Bjorling, E., Lindskog, C., Oksvold, P., Linne, J., Kampf, C., Hober, S., et al. (2008). A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 7, 825-844. (Pubitemid 351737085)
7. Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
8. Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., Lacroix, A. Z., et al. (2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729-1738. (Pubitemid 37430623)
9. Chen, H., Wang, D., Bai, C., and Wang, X. (2010). Proteomicsbased biomarkers in chronic obstructive pulmonary disease. J Proteome Res 9, 2798-2808.
10. Chenau, J., Michelland, S., De Fraipont, F., Josserand, V., Coll, J. L., Favrot, M. C., et al. (2009). The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res 8, 4579-4591.
11. Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., et al. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289, 3243-3253. (Pubitemid 37430077)
12. Cote, R. G., Reisinger, F., and Martens, L. (2010). jmzML, an open-source Java API for mzML, the PSI standard for MS data. Proteomics 10, 1332-1335.
13. Curb, J. D., Prentice, R. L., Bray, P. F., Langer, R. D., Van Horn, L., Barnabei, V. M., et al. (2006). Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 166, 772-780.
14. Cushman, M., Kuller, L. H., Prentice, R., Rodabough, R. J., Psaty, B. M., Stafford, R. S., et al. (2004). Estrogen plus progestin and risk of venous thrombosis. JAMA 292, 1573-1580. (Pubitemid 39314963)
15. Daub, H., Olsen, J. V., Bairlein, M., Gnad, F., Oppermann, F. S., Korner, R., et al. (2008). Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-448.
16. de la Cuesta, F., Alvarez-Llamas, G., Gil-Dones, F., Martin-Rojas, T., Zubiri, I., Pastor, C., et al. (2009). Tissue proteomics in atherosclerosis: elucidating the molecular mechanisms of cardiovascular diseases. Expert Rev Proteomics 6, 395-409.
17. Faca, V., Pitteri, S. J., Newcomb, L., Glukhova, V., Phanstiel, D., Krasnoselsky, A., et al. (2007). Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 6, 3558-3565. (Pubitemid 47522747)
18. Faca, V. M., and Hanash, S. M. (2009). In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res 69, 728-730.
19. Garge, N., Pan, H., Rowland, M. D., Cargile, B. J., Zhang, X., Cooley, P. C., et al. (2010). Identification of quantitative trait loci underlying proteome variation in human lymphoblastoid cells. Mol Cell Proteomics 9, 1383-1399.
20. Greco, T. M., Seeholzer, S. H., Mak, A., Spruce, L., and Ischiropoulos, H., (2010). Quantitative mass spectrometry-based proteomics reveals the dynamic range of primary mouse astrocyte protein secretion. J Proteome Res 9, 2764-2774.
21. Gundry, R. L., Boheler, K. R., Van Eyk, J. E., and Wollscheid, B. (2008). A novel role for proteomics in the discovery of cellsurface markers on stem cells: Scratching the surface. Proteomics Clin Appl 2, 892-903. (Pubitemid 351943769)
22. Hanash, S. (2004). HUPO initiatives relevant to clinical proteomics. Mol Cell Proteomics 3, 298-301. (Pubitemid 38702084)
23. Hanash, S. M., Pitteri, S. J., and Faca, V. M. (2008). Mining the plasma proteome for cancer biomarkers. Nature 452, 571-579. (Pubitemid 351483371)
24. Hendrix, S. L., Wassertheil-Smoller, S., Johnson, K. C., Howard, B. V., Kooperberg, C., Rossouw, J. E., et al. (2006). Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113, 2425-2434. (Pubitemid 43948050)
25. Hermjakob, H., and Apweiler, R. (2006). The Proteomics Identifications Database (PRIDE) and the ProteomExchange Consortium: making proteomics data accessible. Expert Rev Proteomics 3, 1-3. (Pubitemid 43979386)
26. Hsia, J., Langer, R. D., Manson, J. E., Kuller, L., Johnson, K. C., Hendrix, S. L., et al. (2006). Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166, 357-365. (Pubitemid 43244325)
27. Jackson, R. D., Wactawski-Wende, J., Lacroix, A. Z., Pettinger, M., Yood, R. A., Watts, N. B., et al. (2006). Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res 21, 817-828. (Pubitemid 43787988)
28. Katayama, H., Paczesny, S., Prentice, R., Aragaki, A., Faca, V. M., Pitteri, S. J., et al. (2009). Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 1, 47.
29. Kijanka, G., and Murphy, D. (2009). Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 72, 936-944.
30. Kohnke, P. L., Mulligan, S. P., and Christopherson, R. I. (2009). Membrane proteomics for leukemia classification and drug target identification. Curr Opin Mol Ther 11, 603-610.
31. Kosako, H., Yamaguchi, N., Aranami, C., Ushiyama, M., Kose, S., Imamoto, N., et al. (2009). Phosphoproteomics reveals new ERK MAP kinase targets and links ERK to nucleoporinmediated nuclear transport. Nat Struct Mol Biol 16, 1026-1035.
32. Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349, 523-534. (Pubitemid 36951364)
33. Martinez-Bartolome, S., Blanco, F., and Albar, J. P. (2010). Relevance of proteomics standards for the ProteoRed Spanish organization. J Proteomics 73, 1061-1066.
34. May, M. (2009). From cells, secrets of the secretome leak out. Nat Med 15, 828.
35. Omenn, G. S., States, D. J., Adamski, M., Blackwell, T. W., Menon, M., Hermjakob, H., et al. (2005). Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publiclyavailable database. Proteomics 5, 3226-3245. (Pubitemid 41192032)
36. Paczesny, S., Levine, J. E., Braun, T. M., and Ferrara, J. L. (2009). Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant 15, 33-38.
37. Parikh, K., and Peppelenbosch, M. P. (2010). Kinome profiling of clinical cancer specimens. Cancer Res 70, 2575-2578.
38. Piersma, S. R., Fiedler, U., Span, S., Lingnau, A., Pham, T. V., Hoffmann, S., et al. (2010). Workflow comparison for labelfree, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 9, 1913-1922.
39. Pitteri, S. J., Hanash, S. M., Aragaki, A., Amon, L. M., Chen, L., Busald Buson, T., et al. (2009). Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 1, 121.
40. Pitteri, S. J., Paczesny, S. J., Aragaki, A., Amon, L. M., Lin, C., McIntosh, M. W., et al. (2010). Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med (In-press).
41. Rinschen, M. M., Yu, M. J., Wang, G., Boja, E. S., Hoffert, J. D., Pisitkun, T., et al. (2010). Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci USA 107, 3882-3887.
42. Rossouw, J. E., Anderson, G. L., Prentice, R. L., Lacroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333. (Pubitemid 34761611)
43. Sanchez-Carbayo, M. (2010). Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol 31, 103-112.
44. Service, R. F. (2003). Proteomics. Public projects gear up to chart the protein landscape. Science 302, 1316-1318. (Pubitemid 37452148)
45. Somasundaram, K., Nijaguna, M. B., and Kumar, D. M. (2009). Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 9, 695-707.
46. States, D. J., Omenn, G. S., Blackwell, T. W., Fermin, D., Eng, J., Speicher, D. W., et al. (2006). Challenges in deriving highconfidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 24, 333-338. (Pubitemid 43372157)
47. Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, J. R., Paskett, E. D., et al. (2006). Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295, 1647-1657.
48. Voshol, H., Ehrat, M., Traenkle, J., Bertrand, E., and Van Oostrum, J. (2009). Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J 276, 6871-6879.
49. Waanders, L. F., Chwalek, K., Monetti, M., Kumar, C., Lammert, E., and Mann, M. (2009). Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci USA 106, 18902-18907.
50. Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., et al. (2003). Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289, 2673-2684. (Pubitemid 37430138)
51. Whiteley, G. R., Colantonio, S., Sacconi, A., and Saul, R. G. (2009). Analytical considerations for mass spectrometry profiling in serum biomarker discovery. Clin Lab Med 29, 57-69.
52. Xu, B. J., YAN, W., Jovanovic, B., An, A. Q., Cheng, N., Aakre, M. E., et al. (2010). Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts. Proteomics 10, 2458-2470.
53. Xue, H., Lu, B., Zhang, J., Wu, M., Huang, Q., Wu, Q. et al. (2010). Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 9, 545-555.